ModiQuest and its single asset subsidiary Citryll are discovering and developing therapeutic human antibodies. ModiQuest key areas are autoimmune diseases and oncology and Citryll is developing its therapeutic antibodies against citrullinated histones for the prophylactic and therapeutic treatment of RA and other autoimmune disease.
ModiQuest Research is the CRO arm of the company and offers access to its integrated antibody discovery and optimization platform. Services include antibody generation against hard to drug membrane protein targets using its ModiVacc technology, and antibody discovery by phage display, hybridoma, and B‑cell cloning technologies. Recombinant antibodies can be expressed in bacteria in scFv, scFv‑CL, and Fab formats. Fully human, mouse, or chicken antibodies of different isotypes, or any chimeric antibody required by the client can be expressed in mammalian cell lines.
ModiQuest is an antibody discovery and development company. ModiQuest and its single asset subsidiary, Citryll develop antibody therapeutics and companion diagnostics. Its services arm ModiQuest Research offers high end antibody discovery and preclinical development services.
